GlassScriptPhysician profile
Gabriel Sosne
NPI 1952348443
$8,563.70
in general payments reported to CMS, 2019-2025
26 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $270 · 2021: $1,720 · 2022: $1,685 · 2023: $1,733 · 2024: $1,377 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,405.20 | 2019-2025 | Hydrus Microstent, Rocklatan, Simbrinza |
| New World Medical,INC. | $1,839.85 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Allergan, INC. | $754.95 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $447.63 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Ic-8 Apthera Iol |
| Amgen INC. | $375.44 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $313.76 | 2024-2025 | Xdemvy |
| Abbvie INC. | $281.78 | 2022-2025 | Lumigan |
| Eyevance Pharmaceuticals LLC | $277.54 | 2021 | |
| Biotissue Holdings INC. | $268.50 | 2021-2025 | |
| Aerie Pharmaceuticals, INC. | $249.38 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $224.46 | 2022-2024 | Iolmaster 700, Veracity Surgical |
| Sight Sciences, INC. | $194.54 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $133.39 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $132.58 | 2019-2021 | |
| Ocular Therapeutix, INC. | $125.18 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $121.72 | 2023 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $115.96 | 2023 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $97.64 | 2022 | |
| Rxsight INC | $41.54 | 2022 | |
| Thea Pharma INC. | $41.48 | 2025 | Iyuzeh |
| Dompe US, INC. | $25.66 | 2022 | |
| Glaukos Corporation | $23.23 | 2023 | |
| Kala Pharmaceuticals, INC. | $20.79 | 2019 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $19.60 | 2024 | |
| Omeros Corporation | $17.60 | 2019 | |
| Shire North American Group INC | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Sosne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.